Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist

Comparisin CC/Gonadotropin/GnRH Antagonist and Gonadotropin/GnRH Agonist in IVF Outcome.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00830492

Enrollment

200

Registered

2009-01-28

Start date

2008-01-31

Completion date

2008-12-31

Last updated

2009-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Stimulation

Keywords

clomiphene citrate, GnRH agonist, GnRH antagonist, in vitro fertilization, clinical pregnancy, pregnancy

Brief summary

Objective: To compare the efficacy of using mild ovarian stimulation protocol and conventional stimulation protocol in IVF outcome. Design: Prospective randomized trial Setting: University IVF setting. Patient(s): The study compromised a total 200 subinfertile couple that women had regulary menstruation. Intervention(s): Patients were randomized to treatment clomiphene citrate, gonadotropin and GnRH antagonist (100 patients) or GnRH agonist and gonadotropin ( 100 patients). Main outcome measure: Clinical pregnancy rate. Key Words: clomiphene citrate, GnRH agonist, GnRH antagonist, in vitro fertilization, pregnancy rate.

Interventions

DRUGclomiphene citrate

100 mg from cycle day 3 through 7

PROCEDUREUltrasound

cycle day 8

DRUGGnRH antagonist

Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).

DRUGgonadotopin (HMG)

75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)

DRUGbuserelin

Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.

DRUGrFSH

150-225 IU recombinant FSH (r\_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* female patient age 18-35 years, presence of a regular and proven ovulatory menstruation cycle with a length of 26-35 days * basal FSH \<10 IU/L and body mass index (BMI) of 18-30 (kg/m²) * Indication for IVF were unexplained infertility, mild male factor, tubal factor, early stage endometriosis and cervical factor

Exclusion criteria

* patient requiring ICSI

Design outcomes

Primary

Measure	Time frame
clinical pregnancy rate	2 weeks
ovarian stimulation safety	3weeks

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026